Premix approved in Canada for Glässer’s disease

“Glasser’s disease poses a serious threat, and by providing solutions such as Pulmotil Premix, Elanco can help Canadian hog producers compete in the world marketplace,” says Dr. Marie Anne Paradis, a Senior Research and Development Scientist with Elanco. “This approval in Canada – the first for this disease – is a demonstration of Elanco’s commitment to innovation.”

Elanco received Canadian regulatory approval Oct. 2, 2007, for the sale of Pulmotil Premix as an aid in reducing the severity of Glasser’s disease (porcine polyserositis and arthritis associated with Haemophilus parasuis) when fed to pigs approximately 7 days prior to an anticipated outbreak. Mixing and feeding instructions are on the label (Mix at 2kg/tonne to provide 400 ppm tilmicosin activity per tonne in complete feed). Producers should note that the label has been revised, including a withdrawal time change to 14 days, and they should always strictly follow label directions.

Elanco recommends feeding Pulmotil the first 3 weeks after weaning. This protocol can help an animal make a strong start, which in turn can help producers yield more Full Value Pigs™. Producers also benefit from the convenience of a feed-based regimen.

Pulmotil is available wherever producers currently purchase their in-feed medications. “Recent price reductions have made the payback even more appealing,” says Colin Hatch, Elanco Senior Swine Marketing Associate. “Investing in pigs as early as possible sets them up for success and maximizes their potential as Full Value Pigs.”

Pulmotil Premix is also approved as an aid to reduce the severity of swine respiratory disease associated with Actinobacillus pleuropneumoniae and Pasteurella multocida.

Elanco Animal Health is a global research-based company that develops, manufactures and markets proprietary products to improve the health of animals.

Communities in English

Communities in Spanish

Communities in Portuguese

Premix approved in Canada for Glässer’s disease